North America Ulcerative Colitis Market Size, Share & Industry Trends Analysis Report By Molecule Type (Small Molecules and Biologics), By Disease Type, By Route of Administration, By Country and Growth Forecast, 2022 - 2028

The North America Ulcerative Colitis Market is expected to witness market growth of 5.2% CAGR during the forecast period (2022-2028).

Ulcerative colitis is a type of inflammatory bowel disease that affects a large number of people. It causes ulcers and inflammation in the digestive tract. The innermost lining of the large intestine and the rectum are affected by ulcerative colitis. Ulcerative colitis can strike anyone at any age; however, it is most frequent in persons aged 15 to 30. The symptoms of ulcerative colitis differ from person to person, but they may include diarrhea, blood in the stool, and immunological response in the abdomen.

Ulcerative colitis, the most prevalent sign of inflammatory bowel disease, affects the colon (large intestine lining) and rectum. Diarrhea, belly pain/cramps, and rectum bleeding are the most common symptoms, but other signs and symptoms include sudden and unexplained weight loss, lack of appetite, joint pain, kidney stones, eye disease, thickening of the intestinal wall, blood infection (sepsis), and liver disease. Physical examination with procedures like colonoscopy, endoscopy, biopsy, CT scan, and blood test can be used to diagnose this condition.

The Centers for Disease Control and Prevention (CDC) estimates that between 2.2 and 14.3 cases per 100,000 people are discovered each year. In addition, according to a report published in 2014 by the Crohn's & Colitis Foundation of America (CCFA), 907,000 persons in the United States suffer from ulcerative colitis (statistics based on CCFA research conducted between 2011 and 2014). One of the crucial catalysts for the regional market is the existence of established key players and the growing patient pool of UC patients. Moreover, the sophisticated healthcare system is a key supporting factor for the regional market. In March 2019, Johnson & Johnson Services Inc. released additional findings from the Phase III UNIFI study, suggesting that STELARA is effective in adults with mild to severe ulcerative colitis.

The US market dominated the North America Ulcerative Colitis Market by Country 2021, and is expected to continue to be a dominant market till 2028; thereby, achieving a market value of $2,501 million by 2028. The Canada market is experiencing a CAGR of 7.6% during (2022-2028). Additionally, The Mexico market is expected to exhibit a CAGR of 6.6% during (2022-2028).

Based on Molecule Type, the market is segmented into Small Molecules and Biologics. Based on Disease Type, the market is segmented into Mild, Moderate, and Severe. Based on Route of Administration, the market is segmented into Oral and Injectables. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.

The market research report covers the analysis of key stakeholders of the market. Key companies profiled in the report include Abbott Laboratories, Ajinomoto Co., Inc., AstraZeneca PLC, GlaxoSmithKline PLC, Johnson & Johnson, Merck & Co., Inc., Pfizer, Inc., Sanofi S.A., InDex Pharmaceuticals Holding AB, and Eli Lilly And Company.

Scope of the Study

Market Segments Covered in the Report:

ByMolecule Type

• Small Molecules
• Biologics

By Disease Type

• Mild
• Moderate
• Severe

By Route of Administration

• Oral
• Injectables

By Country

• US
• Canada
• Mexico
• Rest of North America

Key Market Players

List of Companies Profiled in the Report:

• Abbott Laboratories
• Ajinomoto Co., Inc.
• AstraZeneca PLC
• GlaxoSmithKline PLC
• Johnson & Johnson
• Merck & Co., Inc.
• Pfizer, Inc.
• Sanofi S.A.
• InDex Pharmaceuticals Holding AB
• Eli Lilly And Company

Unique Offerings from the Publisher

• Exhaustive coverage
• The highest number of market tables and figures
• Subscription-based model available
• Guaranteed best price
• Assured post sales research support with 10% customization free